What Pharma Companies Need to Know about the Inflation Reduction Act (IRA) | Signals by AlphaSense

Описание: In this episode, host Nick Mazing from AlphaSense interviews Emily Coriale, Senior Principal Pricing & Market Access Lead at LifeSci Consulting. They discuss the far-reaching implications of the Inflation Reduction Act (IRA) on the US healthcare system, with a particular focus on drug pricing and price negotiations between the US federal government and pharmaceutical companies, as well as the impact on health plans.

Emily explains that the IRA is the most significant federal legislation in the last 20 years and highlights three main aspects of the act: drug price negotiation, prescription drug inflation rebates, and Medicare Part D redesign. These changes will not only impact profitability, investment, and strategic choices for health plans and manufacturers but also have a domino effect on the entire healthcare system, including patients, insurers, and private funding sources.

As the industry prepares for the IRA's implementation, Emily emphasizes the importance of understanding and mitigating risks, proactive stakeholder communication, and collaboration between healthcare sector partners. This episode provides a comprehensive overview of the IRA's potential impact on pharmaceutical companies and the healthcare value chain.

---
AlphaSense is a market intelligence and search platform used by the world’s leading companies and financial institutions.

→ Learn more about AlphaSense:
https://www.alpha-sense.com

→ Learn more about Stream by AlphaSense:
https://www.streamrg.com

→ Engage with AlphaSense:
Twitter:   / alphasenseinc  
LinkedIn:   / alph.  .
Facebook:   / alphasenseinc  
Instagram:   / alphasenseinc  
Podcast: https://open.spotify.com/show/2Fpmsp1...
Blog: https://www.alpha-sense.com/blog